# Afshin Dowlati

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/afshin-dowlati/

## Facts

| Field | Value |
| --- | --- |
| Citations | 33,065 |
| Field | Lung Cancer Research Studies |
| h-index | 67 |
| i10-index | 247 |
| Last Known Institution | University Hospitals of Cleveland |
| OpenAlex ID | https://openalex.org/A5036587861 |
| ORCID iD | 0000-0003-4535-6839 |
| Works | 719 |

## Researcher papers

Showing 12 of 15.

- [Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer](https://scholariq.org/papers/paclitaxel-carboplatin-alone-or-with-bevacizumab-for-non-small-cell-lung-cancer/)
- [Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children](https://scholariq.org/papers/efficacy-of-larotrectinib-in-i-trk-i-fusion-positive-cancers-in-adults-and/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data](https://scholariq.org/papers/molecular-subtypes-of-small-cell-lung-cancer-a-synthesis-of-human-and-mouse/)
- [Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials](https://scholariq.org/papers/larotrectinib-in-patients-with-trk-fusion-positive-solid-tumours-a-pooled/)
- [Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data](https://scholariq.org/papers/rates-of-initial-and-recurrent-thromboembolic-disease-among-patients-with/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas](https://scholariq.org/papers/phase-i-safety-pharmacokinetics-and-clinical-activity-study-of-lapatinib/)
- [A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo](https://scholariq.org/papers/a-dll3-targeted-antibody-drug-conjugate-eradicates-high-grade-pulmonary/)
- [Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis](https://scholariq.org/papers/chemosensitive-relapse-in-small-cell-lung-cancer-proceeds-through-an-ezh2-slfn11/)
- [Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/small-cell-lung-cancer-version-2-2022-nccn-clinical-practice-guidelines-in/)

## Researcher topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [University Hospitals of Cleveland](https://scholariq.org/institutions/university-hospitals-of-cleveland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.